Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.
| Species | Human |
| Cat.No | ABC-TC4326 |
| Quality Control | All cells test negative for mycoplasma, bacteria, yeast, and fungi. |
| Product Category | Primary Cells |
| Size/Quantity | 1 vial |
| Cell Type | Mononuclear Cell |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Peripheral Blood |
| Disease | Sjogren Syndrome |
| Storage | Liquid Nitrogen |
| Product Type | Diseased Human Peripheral Blood Mononuclear Cells |
Human Sjogren Syndrome Peripheral Blood Mononuclear Cells are isolated from the peripheral blood of patients with Sjogren Syndrome (SS) and are mainly composed of lymphocytes (T cells, B cells, NK cells), monocytes and dendritic cells. Round mononuclear cells; suspension culture; non-adherent.PBMCs play a core role in the SS pathogenesis, especially the overactivation of B cells leading to the production of autoantibodies (such as anti-Ro/SSA, anti-La/SSB), and the imbalance of T cell subsets promoting inflammatory infiltration of glandular tissue. Autoantibodies (anti-Ro/SSA, anti-La/SSB) production by B cells; elevated IFN-γ secretion; altered T cell subset ratios (Th1/Th2 imbalance)In addition, abnormal cytokine secretion of PBMCs (such as IFN-γ) exacerbates the autoimmune response.PBMCs contribute to glandular inflammation and tissue damage through autoimmune mechanisms and cytokine dysregulation.
When you publish your research, please cite our product as "AcceGen Biotech Cat.# XXX-0000". In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
Human Sjogren Syndrome Peripheral Blood Mononuclear Cells can be utilized to investigate the pathological mechanisms underlying Sjogren Syndrome-related diseases, facilitating the exploration of disease biomarkers and targeted therapeutic strategies. Additionally, they serve as a valuable model for evaluating the immunomodulatory effects of targeted therapies on abnormal immune responses in PBMCs.